Integra LifeSciences (NASDAQ:IART) Issues Earnings Results

Integra LifeSciences (NASDAQ:IART) released its quarterly earnings data on Monday. The life sciences company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01, Briefing.com reports. The company had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The company’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.71 earnings per share.

Integra LifeSciences Trading Down 1.1 %

Shares of Integra LifeSciences stock traded down $0.29 on Tuesday, hitting $25.13. 791,537 shares of the company’s stock traded hands, compared to its average volume of 1,121,136. Integra LifeSciences has a one year low of $22.36 and a one year high of $46.09. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The stock has a market capitalization of $1.98 billion, a PE ratio of 50.84, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11. The firm’s 50-day moving average price is $29.72 and its two-hundred day moving average price is $33.65.

Insider Buying and Selling

In related news, Chairman Stuart Essig bought 52,641 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were purchased at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the completion of the purchase, the chairman now owns 487,922 shares of the company’s stock, valued at approximately $13,900,897.78. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 3.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Citigroup cut shares of Integra LifeSciences from a “neutral” rating to a “sell” rating and cut their target price for the company from $30.00 to $23.00 in a research note on Tuesday. Oppenheimer downgraded Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 7th. Wells Fargo & Company cut shares of Integra LifeSciences from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $45.00 to $25.00 in a research report on Tuesday, May 7th. Finally, JMP Securities reduced their target price on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating on the stock in a research report on Tuesday, May 7th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences has a consensus rating of “Hold” and an average price target of $29.88.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.